SEARCH:   Advanced

Blood, 15 July 2004, Vol. 104, No. 2, pp. 321-327. Prepublished online as a Blood First Edition Paper on March 30, 2004; DOI 10.1182/blood-2003-07-2252. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-07-2252v1 104/2/321    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Casadevall, N. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Casadevall, N. Articles by Fenaux, P. Related Collections Neoplasia Red Cells Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Nicole Casadevall, Pierre Durieux, Stéphanie Dubois, François Hemery, Eric Lepage, Marie-Catherine Quarré, Gandhi Damaj, Stéphane Giraudier, Agnès Guerci, Guy Laurent, Hervé Dombret, Christine Chomienne, Vincent Ribrag, Aspasia Stamatoullas, Jean-Pierre Marie, Anne Vekhoff, Frédéric Maloisel, Robert Navarro, François Dreyfus, and Pierre Fenaux, for the Groupe Français des Myélodysplasies From the Service d'Hématologie Biologique et Clinique, Hôtel Dieu, Assistance Publique Hôpitaux de Paris (AP-HP), Paris; Santé Publique et Informatique Médicale, Hôpital Européen Georges Pompidou (HEGP), Paris; Unité d'Information Médicale, Hôpital Henri Mondor, Créteil; Services d'Hématologie, Hôpital Cochin, Paris; Hôpital Necker, Paris; Hôpital Henri Mondor, Créteil; Centre Hospitalier Universitaire (CHU) Nancy-Brabois; Hôpital Purpan, Toulouse; Hôpital Saint-Louis, Paris; Institut Gustave Roussy, Villejuif; Centre Henri Becquerel, Rouen; Hôpital de Hautepierre, Strasbourg; Hôpital Lapeyronie, Montpellier; and CHU de Lille, France. In myelodysplastic syndromes (MDS), anemia responds to recombinant human erythropoietin (rHuEPO) alone and in combination with recombinant human granulocyte-colony-stimulating factor (rHuGCSF) in 10% to 20% and in 35% to 40% of patients, respectively. We randomly divided 60 patients with low-grade anemic MDS and serum EPO levels lower than 500 IU/L (500 mU/mL) into 2 groups: rHuEPO + rHuG-CSF (arm A) and supportive care (arm B). After 12 weeks, those who had erythroid responses were given rHuEPO alone for 40 additional weeks. They were also given rHuG-CSF if they had relapses. A response was considered major if the hemoglobin (Hb) level was 115 g/L (11.5 g/dL) or higher and minor Hb increase was 15 g/L (1.5 g/dL) or more or if it remained stable without transfusion. Ten of 24 patients responded in arm A, and 0 of 26 responded in arm B (P = .01). Eight patients in arm A continued rHuEPO therapy alone, and 6 had relapses. Responses were always restored when rHuG-CSF was reintroduced. Mean direct costs per patient were 26 723 euros ( 26 723) (arm A) and 8746 (arm B). Quality of life was aszsessed with a Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale. Similar percentages of patients from both arms showed significant clinical improvement. rHuEPO plus rHuG-CSF led to responses in 41.7% of MDS patients. This treatment was expensive. No effect on quality of life was demonstrated. (Blood. 2004;104: 321-327) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges Roberto Stasi, Sergio Amadori, Adrian C. Newland, Drew Provan, Nicole Casadevall, Pierre Durieux, Francois Dreyfus, and Pierre Fenaux Blood 2004 104: 2201-2202. [Full Text] [PDF] This article has been cited by other articles: S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood, January 15, 2008; 111(2): 574 - 582. [Abstract] [Full Text] [PDF] J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al. Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update J. Clin. Oncol., January 1, 2008; 26(1): 132 - 149. [Abstract] [Full Text] [PDF] J. D. Rizzo, M. R. Somerfield, K. L. Hagerty, J. Seidenfeld, J. Bohlius, C. L. Bennett, D. F. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update Blood, January 1, 2008; 111(1): 25 - 41. [Abstract] [Full Text] [PDF] S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis Oncologist, October 1, 2007; 12(10): 1264 - 1273. [Abstract] [Full Text] [PDF] C. Kelaidi, S. Park, S. Brechignac, L. Mannone, N. Vey, H. Dombret, L. Aljassem, A. Stamatoullas, L. Ades, S. Giraudier, et al. Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2678 - 2678. [Abstract] [PDF] B. D. Cheson, P. L. Greenberg, J. M. Bennett, B. Lowenberg, P. W. Wijermans, S. D. Nimer, A. Pinto, M. Beran, T. M. de Witte, R. M. Stone, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood, July 15, 2006; 108(2): 419 - 425. [Abstract] [Full Text] [PDF] R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann. Onc., December 1, 2005; 16(12): 1921 - 1927. [Abstract] [Full Text] [PDF] P. Fenaux and L. Ades Erythropoietin for the anemia of low-risk myelodysplastic syndromes Blood, August 1, 2005; 106(3): 768 - 769. [Full Text] [PDF] M. Jadersten, S. M. Montgomery, I. Dybedal, A. Porwit-MacDonald, and E. Hellstrom-Lindberg Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF Blood, August 1, 2005; 106(3): 803 - 811. [Abstract] [Full Text] [PDF] Y.-E. Claessens, S. Park, A. Dubart-Kupperschmitt, V. Mariot, C. Garrido, S. Chretien, F. Dreyfus, C. Lacombe, P. Mayeux, and M. Fontenay Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD Blood, May 15, 2005; 105(10): 4035 - 4042. [Abstract] [Full Text] [PDF] E. Hellstrom-Lindberg Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents Hematology, January 1, 2005; 2005(1): 161 - 166. [Abstract] [Full Text] [PDF] R. Stasi, S. Amadori, A. C. Newland, D. Provan, N. Casadevall, P. Durieux, F. Dreyfus, and P. Fenaux Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges Blood, October 1, 2004; 104(7): 2201 - 2202. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020